Correction:CS MEDICA A/S: Publication of annual report 2022/2023

CS MEDICA A/S posted yesterday a press release releasing its annual report for 2022/2023.  The press release was erroneously missing information about the auditor’s report including a modified statement.

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby publishes its annual report for the period October 2022 – September 2023, including the auditor’s report. It must be noted that the auditor’s report includes the below modified statement. 

Significant uncertainty regarding continued operations
It is imperative to highlight the content of note 0 and in accounting policies under the section “Critical accounting judgments and key sources of estimation uncertainty”, which describes the significant uncertainty associated with revenue and the entered investment agreement. Our conclusion remains unmodified regarding this matter.”

The report is available as an attached document to this press release and on the Company’s website (www.cs-medica.com).

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: